Synthesis of ester-linked glycoside prodrug of taxol, i.e., 7-glycolyltaxol 2''-O-α-D-glucopyranoside, was investigated by chemical synthetic procedure. The encapsulation efficiency and loading efficiency of taxol for liposomes was much improved by modification with glucosyl ester group. The immunoliposomes containing the glycoside prodrug of taxol, i.e., 7-glycolyltaxol 2''-O-α-D-glucopyranoside, exhibited effective anti-tumor activities.
Taxol (paclitaxel) is classified as a taxane diterpenoid, which shows inhibitory action against a variety of tumors [1] . The antitumor compound has been recognized as effective and widely used drug for the treatment of ovarian, breast, and lung cancers. In spite of its effective pharmacological activities, taxol has shortcomings such as low solubility in water.
Glycosylation has attracted pharmacological attention, because the glycosylation of bioactive compounds can enhance their watersolubility, physicochemical stability, and biological half-life [2] [3] [4] [5] [6] [7] . In plant cells, glycosylation reaction has diverse functions such as activation of biosynthetic intermediates and detoxification of toxic compounds generated from environment. Many of secondary metabolites such as saponins and anthocyanins, which are accumulated in the form of glycosides in plants, have specific physiological activities and have been widely used in folk medicines. These pharmacologically active glycosides might be considered as the prodrugs of aglycone compounds.
We report here the synthesis of highly water-soluble ester-linked glycoside prodrug of taxol, i.e., 7-glycolyltaxol 2''-O-α-Dglucopyranoside, and its drug delivery system using immunoliposome targeted with trastuzumab and cetuximab.
Commercially available taxol was treated with TESCl and N,Ndiisopropylethylamine as a base in methylene chloride, providing 2'-triethylsilyloxytaxol (2'-TES-TX) at 97% yield, which was reacted with protected α-glucosyloxyacetic acid using EDCI/DMAP/CH 2 Cl 2 to give 2'-TES-7-glycolyltaxol 2''-O-α-Dglucopyranoside at 78% yield. Triethylsilyl, trityl and benzyl groups were cleanly removed in a single step through a catalytic hydrogenation, providing 7-glycolyltaxol 2''-O-α-D-glucopyranoside (gTX) (Figure 1 ) at 83% yield. Highly hydrophobic compounds such as taxanes are very difficult to encapsulate into the inner water-core of liposome (L). The TEM image of liposomes (gTX-L), which had been treated by electroporation with 7-glycolyltaxol 2''-O-α-D-glucopyranoside (gTX), showed that the inner water-core of liposomes was formed encapsulating 7-glycolyltaxol 2''-O-α-D-glucopyranoside (Figure 2 (A)), whereas water-core was not formed in the case of liposomes electroporated with TX (TX-L) (Figure 2 (B) ). The encapsulation efficiency (EE) and loading efficiency (LE) of taxol for liposome were 12% and 1.2%, respectively. On the other hand, EE and LE values of 7-glycolyltaxol 2''-O-α-D-glucopyranoside for liposome were 64% and 7.3%, respectively. The EE and LE values of taxol were much improved by modification with glucosyl ester group. The results obtained here suggest that taxol was incorporated into the hydrophobic phase of the lipid bilayer of liposomes. However, the capacity of incorporation for taxol into the lipid bilayer of liposomes is physically limited. On the other hand, 7-glycolyltaxol 2''-O-α-D-glucopyranoside (gTX) was efficiently incorporated into the comparatively large inner water-core of liposomes.
Trastuzumab and cetuximab were individually bonded to the liposomes encapsulating 7-glycolyltaxol 2''-O-α-D-glucopyranoside as described in Experimental to give each immunoliposomes. We 3 , that of the mouse injected with trastuzumab-targeted-gTX-IL was 270 mm 3 . The HT-29 tumor volume at day 30 of PBS-injected mouse (control) was 2510 mm 3 , whereas that of the mouse injected with cetuximab-targeted-gTX-IL was 320 mm 3 . Each gTX-IL significantly inhibited tumor growth demonstrating the longest survival period of the mice.
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Thus, an ester-linked glycoside prodrug of taxol i.e. Preparation of immunoliposome containing glycoside prodrug of taxol: 7-Glycolyltaxol 2''-O-α-D-glucopyranoside was encapsulated in the liposome, to which maleimide functional group had been introduced by using 1 mol% Mal-PEG-DSPE. SH groups were introduced to trastuzumab or cetuximab by treatment with 2-iminothiolane or 3-(2-pyridyldithio)propionic-acid-Nhydroxy-succinimide-ester then Tris(2-carboxyethyl)-phosphinehydrochloride. The mixture was subsequently incubated for 1 h at room temperature in the dark to give immunoliposome containing 7-glycolyltaxol 2''-O-α-D-glucopyranoside.
Anti-tumor activity in vivo:
The in vivo anti-tumor effects of gTX-IL were evaluated using HT-29 cells that were xenograft into nude mice. When tumor volumes reached 200-300 mm 3 , tumor-bearing mice were randomly divided into several groups. gTX-IL and PBS-IL was injected via the tail vein. The total injected dose of gTX-IL was 150 mg/kg gTX with three equivalent doses every three days. PBS-IL was also injected as a control at a concentration at which the amount of lipid equivalent to that contained in gTX-IL. Tumor volume was measured for 30 days.
